IP Library Granted Patent US 11,505,583
Granted Patent B2
US 11,505,583 · App. 17/045,704 · Granted Nov 22, 2022

Proteins for the treatment of epithelial barrier function disorders

Inventors: Cristina N. Butterfield (Oakland, CA); Daniela Keilberg (San Bruno, CA); Andrew W. Goodyear (Pacifica, CA); Andrew W. Han (San Francisco, CA)
Assignee: Second Genome, Inc.
C07K14/47A61K35/74A61P1/04A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,505,583
App. No.
17/045,704
Granted
Nov 22, 2022
Kind
B2
Abstract

The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

Claims (16)

1. A protein consisting of an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 34, wherein the amino acid sequence has at least one amino acid substitution relative to SEQ ID NO:34.

2. The protein of claim 1 , wherein the amino acid at position 76 is valine.

3. The protein of claim 1 , wherein the amino acid at position 80 is serine.

4. The protein of claim 1 , wherein the amino acid at position 76 is valine, and the amino acid at position 80 is serine.

5. The protein of claim 1 , wherein the amino acid at position 13 is aspartic acid.

6. The protein of claim 1 , wherein the amino acid at position 13 is aspartic acid, and the amino acid at position 76 is valine, and the amino acid at position 80 is serine.

7. The protein of claim 1 , wherein the amino acid at position 12 is serine.

8. The protein of claim 1 , wherein the amino acid at position 12 is serine, and the amino acid at position 76 is valine, and the amino acid at position 80 is serine.

9. The protein of claim 1 , wherein the amino acid at position 76 is not cysteine, the amino acid at position 80 is not cysteine, and the amino acid at position 12 is not asparagine.

10. The protein of claim 1 , wherein the protein is a synthetic therapeutic protein.

11. A pharmaceutical composition, comprising: the protein of claim 1 and a pharmaceutically acceptable carrier.

12. The protein of claim 1 , consisting of the amino acid sequence of SEQ ID NO: 38.

13. The protein of claim 1 , consisting of the amino acid sequence of SEQ ID NO: 39.

14. The protein of claim 1 , consisting of the amino acid sequence of SEQ ID NO: 40.

15. A pharmaceutical composition comprising the protein of claim 14 and a pharmaceutically acceptable carrier.

16. A protein, consisting of an amino acid sequence having 1, 2, 3, 4, or 5 amino acid substitutions relative to SEQ ID NO:34.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2024
From: SECOND GENOME, INC.
To: GENEVIVE, INC.
Reel/Frame 065994/0042 →
Continuity (2)
Provisional Application 62654083 · Apr 6, 2018
Related Publication 20210230236A1 · Jul 29, 2021